NeoGenomics (NEO) Reports In-Line Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
October 29, 2015 7:02 AM EDTFT. MYERS, Fla., Oct. 29, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2015.
Third Quarter 2015 Highlights:
25% growth in base(1) test volume 8% growth in consolidated revenue despite $1.9 million reduction in FISH reimbursement 12.5% reduction in Avg. Cost per Test in base(1) business Adjusted EBITDA(2) increase to a record high $2.8 million and EPS of ($.00) per shareConsolidated Revenue for the third... More
NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services
October 28, 2015 7:08 PM EDTFT. MYERS, Fla., Oct. 28, 2015 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today an amended Strategic Alliance Agreement with Covance Central Laboratory Services.Â
The Strategic Alliance Agreement, originally executed on Nov. 18, 2013, established NeoGenomics and Covance as mutually exclusive partners for the provision of NeoGenomics' specialty laboratory services, including certain anatomic pathology and histology testing, for Covance's central laboratory customers. The amendment, which reflects the February 2015 merger of Covance and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), will... More
